Literature DB >> 29363541

Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease.

Tomohiro Yamakawa1, Hiroyuki Ohigashi1, Daigo Hashimoto1, Eiko Hayase1, Shuichiro Takahashi1, Miyono Miyazaki2, Kenjiro Minomi2, Masahiro Onozawa1, Yoshiro Niitsu3, Takanori Teshima1.   

Abstract

Chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (SCT) is characterized by multiorgan fibrosis and profoundly affects the quality of life of transplant survivors. Heat shock protein 47 (HSP47), a collagen-specific molecular chaperone, plays a critical role in collagen synthesis in myofibroblasts. We explored the role of HSP47 in the fibrotic process of cutaneous chronic GVHD in mice. Immunohistochemical analysis showed massive fibrosis with elevated amounts of collagen deposits and accumulation of F4/80+ macrophages, as well as myofibroblasts expressing HSP47 and retinol-binding protein 1 in the skin after allogeneic SCT. Repeated injection of anti-colony-stimulating factor (CSF-1) receptor-blocking antibodies significantly reduced HSP47+ myofibroblasts in the skin, indicating a macrophage-dependent accumulation of myofibroblasts. Vitamin A-coupled liposomes carrying HSP47 small interfering RNA (siRNA) (VA-lip HSP47) delivered HSP47 siRNA to cells expressing vitamin A receptors and knocked down their HSP47 in vitro. Intravenously injected VA-lip HSP47 were specifically distributed to skin fibrotic lesions and did not affect collagen synthesis in healthy skin. VA-lip HSP47 knocked down HSP47 expression in myofibroblasts and significantly reduced collagen deposition without inducing systemic immunosuppression. It also abrogated fibrosis in the salivary glands. These results highlight a cascade of fibrosis in chronic GVHD; macrophage production of transforming growth factor β mediates fibroblast differentiation to HSP47+ myofibroblasts that produce collagen. VA-lip HSP47 represent a novel strategy to modulate fibrosis in chronic GVHD by targeting HSP47+ myofibroblasts without inducing immunosuppression.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29363541     DOI: 10.1182/blood-2017-04-779934

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD.

Authors:  Hiroyuki Ohigashi; Daigo Hashimoto; Eiko Hayase; Shuichiro Takahashi; Takahide Ara; Tomohiro Yamakawa; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Takanori Teshima
Journal:  Blood Adv       Date:  2019-04-09

Review 2.  Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.

Authors:  Amjad Ali Khan; Khaled S Allemailem; Saleh A Almatroodi; Ahmed Almatroudi; Arshad Husain Rahmani
Journal:  3 Biotech       Date:  2020-03-10       Impact factor: 2.406

3.  siRNA Therapeutics in Ocular Diseases.

Authors:  Javier Moreno-Montañés; Anne-Marie Bleau; Tamara Martínez; Beatriz Vargas; María Victoria González; Ana Isabel Jiménez
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Roles of the endoplasmic reticulum-resident, collagen-specific molecular chaperone Hsp47 in vertebrate cells and human disease.

Authors:  Shinya Ito; Kazuhiro Nagata
Journal:  J Biol Chem       Date:  2018-12-12       Impact factor: 5.157

Review 5.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report.

Authors:  Kirsten M Williams; Yoshihiro Inamoto; Annie Im; Betty Hamilton; John Koreth; Mukta Arora; Iskra Pusic; Jacqueline W Mays; Paul A Carpenter; Leo Luznik; Pavan Reddy; Jerome Ritz; Hildegard Greinix; Sophie Paczesny; Bruce R Blazar; Joseph Pidala; Corey Cutler; Daniel Wolff; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Paul J Martin; Gerard Socie; Stefanie Sarantopoulos
Journal:  Transplant Cell Ther       Date:  2021-03-02

6.  Reversal of Vocal Fold Mucosal Fibrosis Using siRNA against the Collagen-Specific Chaperone Serpinh1.

Authors:  Yo Kishimoto; Masaru Yamashita; Alice Wei; Yutaka Toya; Shuyun Ye; Christina Kendziorski; Nathan V Welham
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-22       Impact factor: 8.886

7.  miR-29a is a potential protective factor for fibrogenesis in gluteal muscle contracture.

Authors:  R Zhou; S Ren; C Li; X Zhang; W Zhang
Journal:  Physiol Res       Date:  2020-05-29       Impact factor: 1.881

8.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10

Review 9.  Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease.

Authors:  Pedro Santos E Sousa; Clare L Bennett; Ronjon Chakraverty
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

10.  Xiaochaihu decorction relieves liver fibrosis caused by Schistosoma japonicum infection via the HSP47/TGF-β pathway.

Authors:  Yuzheng Huang; Jin Lu; Yongliang Xu; Chunrong Xiong; Deshen Tong; Nannan Hu; Haitao Yang
Journal:  Parasit Vectors       Date:  2020-05-14       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.